Direct ultra-sensitive detection of pathogen biomarkers in blood could provide a universal strategy for diagnosis of bacterial infections, which remain a leading cause of morbidity and mortality in many areas of the world. Many factors complicate diagnosis, including the presence of multiple co-infections in a given patient, and lack of infrastructure in rural settings. In some pediatric patients, such as those in areas with poor resources, an additional challenge exists with low sample volumes due to age and other health factors such as anemia and dehydration. Our team is working on developing novel diagnostic assays, with a waveguide-based biosensor platform, to rapidly and specifically identify pathogen biomarkers from small samples of serum or plasma, allowing for the timely and sensitive diagnosis of infection at the point of care. In addition to the platform, we have developed novel membrane insertion and lipoprotein capture assay methods, to capture lipidated pathogen biomarkers in aqueous blood, by virtue of their interactions with host lipoprotein carriers. Herein, we demonstrate our efforts to adapt the lipoprotein capture assay for the detection of small concentrations of pathogen-secreted lipopolysaccharides in aqueous blood, with the ultimate aim of diagnosing Gram-negative infections effectively.
INTRODUCTION
Salmonella infections are one of the leading causes of illness in the United States 1 , as well as worldwide 2 . In the US, most Salmonella infections cause gastrointestinal distress and usually resolve within a few days. However, in sub-Saharan Africa, Salmonella infections can lead to potentially fatal infections in blood 2 . The case fatality rate for non-Typhi Salmonella infections in sub-Saharan Africa is 4.4-27% in children and 22-47% in adults 2 . Such infections in blood are challenging to detect because of low bacterial counts 3 . The gold standard for Salmonella detection requires culturing the pathogen on special media, which can take 24-48 hours. Serological tests are widely used, but they are not always reliable 4 . There is an additional challenge in pediatric populations from underdeveloped countries where many patients are undernourished or anemic, which makes collection of a sufficient volume blood difficult.
Pathogens secrete specific biomarkers and virulence factors in the host during infection. Lipopolysaccharide (LPS) is a part of the bacterial outer membrane of Gram-negative bacteria, including Salmonella, which is released by the pathogen in host blood during the course of infection, and recognized by the innate immune receptors 5 . Measurement of LPS in host blood is thus an indicator of active infection. LPS is an amphiphilic molecule, containing both hydrophobic and hydrophilic properties 10, 11 , which allows it to associate with host lipoproteins found in blood [6] [7] [8] [9] . In fact, the molecule is rarely found in a monomeric form in aqueous milieu and can self-aggregate 10, 11 or form complex assemblies 12 . Association with carrier lipoproteins is a mechanism utilized by the human body to neutralize LPS in blood during an infection, and for the transport of such lipidated moieties within the body 9 .
A (ApoA) whereas with LDL, it is largely made of different Apolipoprotein B (ApoB) proteins 14 . Lipoproteins in blood play a major role in the transport of lipids from the bloodstream to the liver. The same process also works in clearing amphiphilic pathogen biomarkers such as LPS, lipoteichoic acid (LTA) and lipoarabinomannan (LAM) 15, 16 , and others. Due to the amphiphilic nature of LPS, lipoproteins bind to the lipid portion of it 15, 17 and transport it to the liver to be cleared in a similar pathway as that used to clear cholesterol 15, 17 . This pathway, and the association of LPS with lipoproteins is also critical in innate immune recognition 15 . We have exploited the amphiphilic biochemistry of LPS, and its association with host lipoproteins to develop two assay architectures for the direct detection of the molecule in aqueous blood: membrane insertion and lipoprotein capture.
Membrane insertion is based on the natural association of lipidic/amphiphilic molecules with a supported lipid bilayer, in our case, on the surface of the waveguide 10, 17, 19 . In an aqueous environment, lipidic targets can be captured on a supported lipid bilayer by virtue of their natural affinity for each other, which facilitates partitioning of the biomarker onto the supported bilayer. After, the antigen is immobilized onto the bilayer, it is then detected using a fluorescently-labeled reporter antibody. This allows for the antigen to be detected in a physiological conformation in an aqueous matrix despite its amphiphilic nature 11, 12, 16 . Further, this detection strategy requires only one reporter antibody and hence can be applied to small molecules that are challenging to detect using conventional strategies 20 .
Lipoprotein capture assay is another novel assay format developed at Los Alamos National Laboratory (LANL), which is tailored to capture amphiphilic biomarkers associated with host carrier lipoproteins in serum. In this sandwich-style assay, biotin-streptavidin chemistry is used to immobilize biotinylated capture antibodies on a functionalized waveguide. These antibodies target host lipoproteins that the biomarker of interest is known to associate with. Subsequently, the sample is added, and the lipoproteins are captured on the waveguide surface. If the biomarker of interest is also captured, it is detected by a fluorescently labeled reporter antibody 16 . This allows for detection of antigens associated with HDL and LDL in patient sera.
The detection platform, a waveguide biosensor 19, 21 developed at LANL, utilizes an evanescent field to sensitively detect biomarkers from mixed matrices. Single-mode planar optical waveguides made of silicon oxynitride (SiONx), with a 10 nm deposit of silicon dioxide were functionalized on the surface for biological assays 19, 21 . The different materials with different refractive indices allow for total internal reflection to occur 19, 21, 22 within the waveguide. Some of the reflected light escapes the plane of the waveguide, forming an evanescent field. The evanescent field produced is about 150 to 200 nm from the waveguide surface, and rapidly decays with increasing distance from the surface 21 . Detection within the evanescent field facilitates increased sensitivity and decreased background, as the fluorescence signal is read only within a small area where biological interactions are occurring within the flow cell 119, 21, 22 . This platform provides an ideal method for detection of low concentration antigens from small volume samples. We have developed and optimized different surface functionalization chemistries for use with this platform 21, 23, 24 . Also, it is often required to detect a suite of biomarker signatures rather than one single molecule. To facilitate this, our team has developed both multiplex assays and multichannel waveguides for the simultaneous detection of several signatures in a single low-volume sample at the point of care 25, 26 . Several assays have been developed or adapted to this platform including sandwich assays 19,23,27 membrane insertion 10, 17, 28 and lipoprotein capture assays 16 . The assays used in this work are membrane insertion and lipoprotein capture.
METHODS

Lipid preparation
Lipids used were 1% biotinylated 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC, Avanti® Polar Lipids), as previously described 21, 25 . Briefly, 2 mM DOPC and 1% (v/v, relative to DOPC) cap-Biotin (Avanti®) in chloroform were mixed together in a glass tube. The chloroform was removed by drying the sample under a stream of argon, and lipids were re-solubilized in phosphate buffered saline (PBS), followed by mixing at 120 rpm at room temperature (RT) for 1 hour (h). The resulting suspension was subjected to 8 freeze-thaw cycles in liquid nitrogen and warm water. The lipids were subsequently sonicated using a Branson probe sonicator for 6 min, with 1 s on and 1 s off. Lipids were stored at 4°C until use.
Waveguide preparation
Glass coverslips and waveguides were cleaned as previously described 21, 27 . To clean, both were bath sonicated for 5 min each in chloroform, ethanol and water, then dried under argon and exposed to UV light and Ozone (UVOCS Inc.) for 40 min, to remove any remaining organic deposits from the surfaces.
To functionalize the waveguides for biological assays, the surface was coated with prepared phospholipid bilayers (section 2.1) using previously established methods 10 . Briefly, the waveguide flow cell was prepared by attaching the cleaned glass coverslip using a silicone gasket (Grace Bio-Labs), with a channel cut in the middle, to the cleaned waveguide 21, 27 . The lipids prepared were flowed through the channel and once filled, the ends were sealed. The flow cell was incubated at 4°C overnight to allow the lipids to organize into stable bilayers on the waveguide surface. After overnight incubation, the assembled flow cell was placed in mounting hardware for experimental measurements.
Lysate preparation
Lipid lysates were prepared from control isolate S. Typhimurium 14028 from the American Type Culture Collection (ATCC), using the chloroform-methanol lipid extraction method, modified from the Bligh and Dyer method 29 . Briefly, bacterial cultures were grown on Tryptic Soy Agar (TSA, Becton Dickinson) plates overnight, then scraped into 10 mL of sterile water and centrifuged. The supernatant was removed and 10 mL of both chloroform and methanol were added to the pellet retained in the tube. Finally, 3 mL of water was added to the mixture. The tubes were vortexed to re-suspend the pellet, and then incubated at RT with shaking for 2 h. The suspension was centrifuged at 10,000 rpm for 30 min and the two resulting layers were both collected, and stored separately. The procedure was repeated once with the pellet from the previous step. The lysates were then purified of chloroform and methanol by rotary evaporation. Lysates were stored at -80°C until use.
Antigens and antibodies
LPS samples from Salmonella Typhimurium were purchased from List Biological Laboratories. For membrane insertion assays, LPS was prepared in 5 mg/mL stock in water, bath sonicated for 15 min, and diluted to the working concentrations in PBS. The dilutions were re-sonicated for 15 min prior to every experiment. The lipid lysates from the control isolate were also sonicated for 15 min prior to dilution in PBS (100-fold dilution) and then sonicated 15 min before use 10, 30 .
For lipoprotein capture assays, the sonicated lipid lysates were diluted 100-fold in sterile serum (Fisher Bioreagents) prior to use. The serum dilutions were prepared as controls for patient samples and stored at 4°C. Serum dilutions were not sonicated prior to assays.
For detection of Salmonella, a polyclonal antibody (pAb) anti-Salmonella PA17244 (Invitrogen) was used as the reporter. The reporter antibodies were fluorescently labeled with Alexa Fluor® 647 (af647, Life Technologies) per kit instructions, and provided the positive read-out upon interaction with Salmonella LPS in the flow cell. Biotinylated monoclonal antibodies (mAb) anti-Apolipoprotein AI and anti-Apolipoprotein B (ab20898 and ab27630, Abcam) were used as capture antibodies in the lipoprotein capture assays to pull-down HDL assemblies from serum on the functionalized lipid bilayer.
Salmonella LPS membrane insertion assays
Concentration dependent LPS insertion assays were established using Salmonella Typhimurium LPS in PBS from 200 µg/ml to 3.13 µg/ml using pAb PA17244-af647 as the reporter antibody. Membrane insertion assays were performed with S. Typhimurium lipid lysate dilutions, using pAb PA17244-af647 as the reporter antibody.
The set-up of the flow cell, optimization of the platform and experimental flow has been described elsewhere 10,16,17,19,23,27,28,30. Briefly, flow cells were prepared, inserted into the platform, and blocked for 1 hr with 2% bovine serum albumin (BSA), then rinsed with wash buffer (0.5% BSA/1X PBS). The laser light was coupled into the grating at 440-445 µW incident power, and signal was adjusted for maximum peak intensity. The background signal was acquired using a spectrometer interface (USB2000, Ocean Optics) attached to the biosensor platform. 200 µL of the fluorescently-labeled reporter antibody (25 nM, PA1-7244-af647) was injected into the flow cell, and incubated for 90 min, RT. This step provides a measurement of the non-specific signal (NSB), which determines the interaction of the fluorescently-labeled antibody with the lipids and other components of the assay system, in the absence of the antigen. The wash and read step was repeated after every addition during the experimental protocol. Following this, 200 µL of the antigen was added and incubated in the flow cell for 2 h. This allowed enough time for the antigen to insert into the bilayers. The specific signal (SB) associated with the interaction of the antibody with LPS partitioned into the supported lipid bilayer on the waveguide surface was then determined by adding 200 µL of the fluorescently-labeled reporter antibody (25 nM, PA1-7244-af647) and incubating for 90 min.
Salmonella lysates lipoprotein capture assays
In serum, Salmonella LPS partitions into carrier lipoproteins such as HDL and LDL. Hence, the membrane insertion assay cannot be applied directly to patient blood/sera for diagnostics, without extensive sample preparation. Therefore, lipoprotein capture assays were developed, which will be used for diagnostic validation in ongoing/future studies in clinical samples. The lipoprotein capture assays were performed using the lipid lysates of Salmonella isolates (ATCC 14028). The lysate was diluted 1:100 in sterile serum, and either used immediately for the 0 h time point, or incubated at 4°C until use. The dilutions were brought to RT and vortexed quickly before injection.
For each experiment, a flow cell was prepared, and control measurements performed as described above (section 2.2). Streptavidin (10 nM, 200 µL in PBS) was added to the flow cell, and incubated for 10 min to allow bonding with the biotinylated supported lipid bilayer (section 2.1). Next, 200 µL of the biotinylated ApoAI and ApoB mAbs (100 nM each) were added and incubated for 45 min. This immobilized the biotinylated mAbs to the membrane bilayer using biotinavidin chemistry. For measurement of NSB, 200 µL of the reporter antibody (25 nM) was added to the flow cell and incubated for 90 min. The lysate dilution (antigen, prepared as in section 2.4) was then added, and incubated for 2 hr, allowing association with the capture antibodies. Subsequently, the reporter antibody was added and incubated for 90 min facilitating binding to the antigen (SB). After rinsing, the fluorescence signal associated with antibody bound to antigen on lipoproteins was measured. All assay steps were performed at RT.
Data processing
Data were graphed between wavelengths 625-825 nm using MS Excel, and the peak intensity at 676 nm was used as endpoint measurement of fluorescence. This is the emission maxima associated with af647. The signal-to-noise ratio was calculated by first subtracting the background signal from both the non-specific and specific signals and then calculating the ratio.
.
RESULTS
LPS membrane insertion assays
S. Typhimurium LPS was detected by membrane insertion (Figure 1 ) over a concentration range of 3.13 µg/mL to 200 µg/mL. The signal is consistently above threshold at 6.25 µg/mL, which is the Limit of Detection of this assay. The association of LPS with the lipid bilayer was not linear because high concentrations of LPS can change the conformation of the lipid membrane due to saturation. This is consistent with previous observations 10 . The tendency of LPS to form aggregates which associate with the membrane would also affect the binding affinity 10, 12, 30 . These assays are being repeated in serum. NSB is the non-specific binding of the reporter pAb labeled with af647, which averaged at 66 RFU (n=7 measurements), shown here in pale blue.
Lysate membrane insertion assays
The crude lysate preparations with an unknown concentration of LPS were diluted in PBS, and the antigens were detected by membrane insertion (Figure 2 ). The crude lipid extracts were then diluted in serum in order to assess uptake/binding to serum carrier proteins. Indeed, a time dependent decrease in signal was observed, as measured by membrane insertion, which indicates association of the LPS with lipoproteins or other moieties in serum. This decrease saturates in 24 hours (Figure 3 ). The sequestration of LPS by serum carrier molecules decreases the usefulness of the membrane insertion assay as a detection method for LPS in serum. -625  645  665  685  705  725  745  765  785 Wavelength (nm)
Lysate lipoprotein capture assays
LPS are able to form aggregates or associate with lipoproteins in blood, as previously mentioned. LPS aggregates were evaluated using the membrane insertion assays described in section 2.5. The association of LPS with HDL and LDL molecules in blood has not been directly evaluated from serum. To study these interactions, the lipoprotein capture assay was adapted from a study previously validated for LAM 16 .
HDL and LDL are lipid nanodisks, which are held together in the aqueous milieu of blood via specific coat proteins, ApoA and ApoB proteins, respectively. In this study both ApoAI and ApoB antibodies were used to capture HDL and LDL to the membrane surface. LPS is known to associate with both HDL and LDL in physiological systems [6] [7] [8] [9] and this was validated through these assay development efforts. As shown in Figure 4 , we observed maximal recovery of LPSspecific fluorescence when both HDL and LDL were captured on the waveguide surface and the LPS associated with them was measured by lipoprotein capture. This method allows for measurement of serum LPS and other amphiphiles that are pre-conjugated with lipoprotein carriers without the need for complex sample processing methods. These assays are being repeated to further validate the results. 
CONCLUSIONS
The waveguide biosensor platform allows for the sensitive detection of bacterial pathogen biomarkers directly from small volumes of sample 10, 16, 17, 19, 23, 27, 28, 30 . While membrane insertion is a sensitive method for the detection of LPS in buffers, LPS in serum is sequestered by lipoproteins, which reduces detection by membrane insertion. By developing immunoassays, which exploit natural processes of host-pathogen interaction that occur within the body in the presence of the pathogen , we can sensitively detect signatures such as LPS even when associated with serum lipoproteins. In this study, we have shown that the lipoprotein capture assay is an excellent method to detect these biomarkers in serum samples. We could recover the signal that was lost when LPS was added to serum, due to its association with serum lipoproteins via a combined HDL-LDL capture assay (Figure 3 ). Additional testing is currently underway to optimize the assay. Further testing with blinded clinical samples will be conducted for assay validation.
